Small Cell Lung Cancer (SCLC) Clinical Trial
Official title:
Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With Small Cell Lung Cancer
The purpose of this clinical trial is to evaluate the safety, tolerability and primary efficacy of JK-1201I in patients with small cell lung cancer (SCLC)
This study is a multi-center, open labeled, single, -combined, with multiple dose escalation trial. The trial consists of dose escalation phase and dose expansion phase; Dose escalation phase: based on the earlier studies, 3 more patients will be added to the 180mg/m2 dose group. The follow-up dose group will adopt the "3+3" design, with 3-6 subjects in each group; include 3 preset dose levels, 220mg/m2, 260mg/m2 and 300mg/m2, respectively. Each subject will receive only one corresponding dose. After the completion of single dose and 21-day DLT observation period, Safety is assessed by the investigator and sponsor, and if the safety evaluation results is favorable, subject will continue to receive the same level of testing compound. Each patient will receive maximum of 4 cycle of treatments. Dose expansion stage: according to the results of the dose increasing stage, dose groups will be selected for expansion. It is expected that 2 to 3 dose groups will enter the expansion stage, and the total number of participants in each dose group will be 20, and a total of 4 cycles of drug administration will be given to each subject. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05652686 -
A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05027100 -
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
|
N/A | |
| Active, not recruiting |
NCT03708328 -
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05740566 -
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT04285866 -
Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.
|
||
| Completed |
NCT03066778 -
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
|
Phase 3 | |
| Not yet recruiting |
NCT04727853 -
Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)
|
Phase 2 | |
| Withdrawn |
NCT02030184 -
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
|
Phase 1/Phase 2 | |
| Completed |
NCT03538028 -
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
|
Phase 1 | |
| Terminated |
NCT01904253 -
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
|
Phase 2 | |
| Withdrawn |
NCT01210131 -
Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)
|
N/A | |
| Terminated |
NCT02934503 -
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
|
Phase 2 | |
| Completed |
NCT02580994 -
Pembrolizumab in Untreated Extensive SCLC
|
Phase 2 | |
| Completed |
NCT03811652 -
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT02628067 -
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
|
Phase 2 | |
| Active, not recruiting |
NCT02769832 -
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
|
Phase 2 | |
| Completed |
NCT02069158 -
Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor
|
Phase 1 | |
| Recruiting |
NCT03460977 -
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
|
Phase 1 |